Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
PHASE4Active, not recruitingINTERVENTIONAL
Enrollment
750
Participants
Timeline
Start Date
March 28, 2024
Primary Completion Date
January 31, 2025
Study Completion Date
January 31, 2025
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
DRUG
SPN-812
SPN-812 (200mg to 600mg once daily)
Trial Locations (1)
10001
ObvioHealth, New York
All Listed Sponsors
lead
Supernus Pharmaceuticals, Inc.
INDUSTRY
NCT06185985 - Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms | Biotech Hunter | Biotech Hunter